New drug GRT6019 takes first step toward duchenne treatment

NCT ID NCT07347548

Completed Disease control Sponsor: Grünenthal GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This early-phase trial tests the safety and tolerability of a new drug called GRT6019 in 24 healthy men. Participants receive multiple doses over 4 weeks and are monitored for side effects and how the drug moves through the body. The goal is to see if GRT6019 is safe enough to study further in people with Duchenne muscular dystrophy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GRT6019
What this could lead to: If safe, this could lead to larger trials testing GRT6019 as a potential treatment for Duchenne muscular dystrophy.
What could go wrong: This is a very early, small trial in healthy men, not patients. It only tests safety and drug levels, not whether it works for DMD. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY (DMD)

Contacts and locations

Locations

Biotrial Clinical Pharmacology Unit

Rennes, 35042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.